Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures

NCT00229242

Last updated date
Study Location
Kingston General Hospital
Kingston, Ontario, K7L 2V7, Canada
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
15-65 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Age 20-65 years;

2. Hypertension with average 24-hour BP of >130 mmHg systolic or >80 mmHg diastolic in spite of treatment with one medication;

3. Office systolic blood pressure >140 mmHg and less than 180mmHg;

4. Able to comprehend and sign the consent form;

5. Able to tolerate either hydrochlorothiazide 25 mg or amlodipine 5 mg daily for 3 weeks during the run-in phase.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Diagnosis of secondary hypertension;


2. Hypertension with systolic BP >180 mmHg in spite of 1 medication;


3. Chronic heart failure requiring diuretics, Angina or coronary syndrome requiring
anti-angina therapy with CCB or beta blockers, or more than 0.4 mg/hr nitroglycerine
patch;


4. Left Ventricular Ejection Fraction (LVEF) <20% or LV end systolic dimension >75 mm;


5. Significant valvular disease such as; more than mild disease of aortic or mitral
valve;


6. Technically sub-optimal acoustic window or regional wall motion abnormalities;


7. Patients currently on both CCB and diuretics for more than 4 weeks;


8. Normal 24 hour ABPM at the end of the run-in period;


9. Physical handicap that precludes adequate performance of 6-minute walk such as
arthritis;


10. Concomitant comorbidity that might compromise ability to evaluate treatment or enhance
risks of therapy, such as: atrial fibrillation with resting ventricular rate of >100
bpm; morbid obesity; uncontrolled diabetes mellitus; severe chronic obstructive
pulmonary disease (COPD); hypertrophic cardiomyopathy; and documented history of
non-compliance with treatment;


11. Any condition or disorder other than hypertension that: Requires prolonged
hospitalization; May limit life expectancy within 2 years; would increase the risk of
participation to the subject (in the opinion of the investigator).

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

HypertensionImpact of an IT-Based and Healthcare Professional Support Program on Patients With High Blood Pressure
NCT00374829
  1. Laval, Quebec
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HypertensionA Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.
NCT00171366
  1. E. Hanover, New Jersey
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HypertensionSTITCH (Simplified Therapeutic Intervention To Control Hypertension)
NCT00129909
  1. London, Ontario
ALL GENDERS
18 Years+
years
MULTIPLE SITES
HypertensionStudy on Internet Medical Models for the Management of Patients With Hypertension in China
NCT03527563
ALL GENDERS
45 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures
Official Title  ICMJE Comparison of Diuretic-based With Non-diuretic Based Hypertension Therapy Using Echocardiographic Measures
Brief Summary MAIN: The benefits of treating high blood pressure successfully to normal levels on heart function are the same regardless of which particular combination of drugs are used. SECONDARY: Measurement of heart function using a comprehensive ultrasound imaging method (Echocardiography) and an objective test of functional ability are better predictors of changes in heart function with successful hypertension treatment, than subjective signs of heart failure.
Detailed Description Successful treatment of hypertension with single medications is very rare. On average successful treatment requires more than 2 medications. These medications work by different methods. One of the ideas behind the use of combinations of medication for hypertension is that benefits are additive. There are unresolved questions about whether the observed benefits are simply related to effective treatment of hypertension, or whether some of the medications have special benefits independent of blood pressure lowering. Each of these contentions has been justified by clinical trials. However these trials have in common the flaw that hypertension is either not effectively controlled in all the treated subjects, or the magnitude of blood pressure change after treatment is different in the groups compared. The result of one of the largest blood pressure clinical trials called ALLHAT trial has recently fuelled this debate. The ALLHAT trial which utilized only subjective symptoms and signs of heart failure, called the FRAMINGHAM score, to determine who has abnormal heart function, implied that diuretics (water pills) were superior to the newer drugs in reducing the frequency of abnormal heart function. This study shared the flaw of previous trials in not having equal blood pressure lowering in the groups. Nevertheless it provided some evidence that argued against the notion that newer drugs were better than older drugs like diuretics. Shortly after the publication of ALLHAT, another trial called ANBP was published showing that the group of drugs that was least effective in ALLHAT was superior to diuretics in preventing important cardiovascular outcomes. Hence, it is not currently clear that there are differences between various drug combinations, if effective and equal blood pressure lowering is achieved. Another finding that may have confounded clinical trials that rely on subjective scores of heart dysfunction such as the ALLHAT, is that a significant proportion of subjects with advanced heart disease are unaware of their heart problem and hence will probably not seek attention. This raises the concern that the true frequency of abnormal heart function might not have been reported in those studies. Using more modern tools such as Echocardiography, a more complete assessment of heart dysfunction can be obtained. In addition objective tests of heart function such as the 6-minute walk distance could yield a more reliable assessment of any worsening or improvement in heart function if performed serially in treated subjects. In view of the above discussion, only a study in which hypertension is effectively and similarly controlled could be used to answer the questions regarding different effects of various drug combinations. Such is this study proposed.
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Hypertension
Intervention  ICMJE Drug: Diuretic-Based or Non-Diuretic Based Hypertension Therapy
Study Arms  ICMJE
  • Active Comparator: 1
    Diuretic-Based Hypertension Therapy
    Intervention: Drug: Diuretic-Based or Non-Diuretic Based Hypertension Therapy
  • Active Comparator: 2
    Non-Diuretic-Based Hypertension Therapy
    Intervention: Drug: Diuretic-Based or Non-Diuretic Based Hypertension Therapy
Publications * Ogunyankin KO, Day AG. Successful treatment of hypertension accounts for improvements in markers of diastolic function - a pilot study comparing hydrochlorothiazide-based and amlodipine-based treatment strategies. Can J Cardiol. 2009 Dec;25(12):e406-12.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 11, 2009)
38
Original Enrollment  ICMJE
 (submitted: September 27, 2005)
50
Actual Study Completion Date  ICMJE March 2007
Actual Primary Completion Date December 2006   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Age 20-65 years;
  2. Hypertension with average 24-hour BP of >130 mmHg systolic or >80 mmHg diastolic in spite of treatment with one medication;
  3. Office systolic blood pressure >140 mmHg and less than 180mmHg;
  4. Able to comprehend and sign the consent form;
  5. Able to tolerate either hydrochlorothiazide 25 mg or amlodipine 5 mg daily for 3 weeks during the run-in phase.

Exclusion Criteria:

  1. Diagnosis of secondary hypertension;
  2. Hypertension with systolic BP >180 mmHg in spite of 1 medication;
  3. Chronic heart failure requiring diuretics, Angina or coronary syndrome requiring anti-angina therapy with CCB or beta blockers, or more than 0.4 mg/hr nitroglycerine patch;
  4. Left Ventricular Ejection Fraction (LVEF) <20% or LV end systolic dimension >75 mm;
  5. Significant valvular disease such as; more than mild disease of aortic or mitral valve;
  6. Technically sub-optimal acoustic window or regional wall motion abnormalities;
  7. Patients currently on both CCB and diuretics for more than 4 weeks;
  8. Normal 24 hour ABPM at the end of the run-in period;
  9. Physical handicap that precludes adequate performance of 6-minute walk such as arthritis;
  10. Concomitant comorbidity that might compromise ability to evaluate treatment or enhance risks of therapy, such as: atrial fibrillation with resting ventricular rate of >100 bpm; morbid obesity; uncontrolled diabetes mellitus; severe chronic obstructive pulmonary disease (COPD); hypertrophic cardiomyopathy; and documented history of non-compliance with treatment;
  11. Any condition or disorder other than hypertension that: Requires prolonged hospitalization; May limit life expectancy within 2 years; would increase the risk of participation to the subject (in the opinion of the investigator).
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 15 Years to 65 Years   (Child, Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00229242
Other Study ID Numbers  ICMJE DMED-676-03
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Dr Kofo Ogunyankin, Queens University
Study Sponsor  ICMJE Queen's University
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Kofo O Ogunyankin, MD, FACCQueen's University
PRS Account Queen's University
Verification Date December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP